Cargando…
MON-022 Enhancing Patient Care: Co-Creation and Validation of a New and Improved Delivery System for Lanreotide Depot/Autogel and Its Evaluation by US Healthcare Professionals
Lanreotide autogel/depot, a somatostatin analogue used to treat patients with acromegaly and gastroenteropancreatic neuroendocrine tumours (GEP-NETs), is currently supplied as a sterile, ready-to-use, single-dose prefilled syringe and is administered subcutaneously. To further enhance patient care,...
Autores principales: | Adelman, Daphne, Truong Thanh, Xuan-Mai, Megret, Clémentine |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Endocrine Society
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6550760/ http://dx.doi.org/10.1210/js.2019-MON-022 |
Ejemplares similares
-
Co-Creation of a Lanreotide Autogel/Depot Syringe for the Treatment of Acromegaly and Neuroendocrine Tumours Through Collaborative Human Factor Studies
por: Adelman, Daphne T., et al.
Publicado: (2019) -
Correction to: Co-Creation of a Lanreotide Autogel/Depot Syringe for the Treatment of Acromegaly and Neuroendocrine Tumours Through Collaborative Human Factor Studies
por: Adelman, Daphne T., et al.
Publicado: (2020) -
MON-013 Nutritional Approach To Autoimmune Thyroiditis (AIT) - The Patients’ And Medical Professionals’ View.
por: Trofimiuk-Muldner, Malgorzata, et al.
Publicado: (2019) -
MON-133 Hyponatremia in Hospital Care
por: Durkan, Maeve Catherine, et al.
Publicado: (2020) -
MON-LB47 An International Simulated Use Study (PRESTO) to Evaluate Nurse Preferences Between the Lanreotide Autogel New Syringe and Octreotide Long-Acting Release Syringe
por: Adelman, Daphne T, et al.
Publicado: (2020)